

# A Post-Market Clinical Follow-up of EARFOLD® Implantable Clip System in general surgical practice

**First published:** 25/10/2016

**Last updated:** 31/03/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS15927

---

### Study ID

22546

---

### DARWIN EU® study

No

---

### Study countries

☐ United Kingdom

---

## Study description

Study is a multicentre, observational study of patients who receive at least one EARFOLD® implant. The overall objective of the study is to assess adverse events (AEs) associated with EARFOLD® implants in usual surgical practice when used for correction of prominent ears. Primary Objective: Characterise and assess the incidence rates of • Infections • Re-operations • Erosions  
Secondary Objectives: 1) Assess the incidence rates of other AEs in patients who receive at least one EARFOLD® implant. 2) Compare the incidence of AEs of EARFOLD® implants with those of standard otoplasty. 3) Aesthetic outcome of surgery as assessed by patient satisfaction. Study Population Inclusion criteria The population will consist of all patients who have received at least one EARFOLD® implant at the trained sites in the United Kingdom. Exclusion criteria: Patients known to have impaired healing (e.g. but not restricted to, Ehlers-Danlos Syndrome or Scleroderma). Patients with body dysmorphic disorder. Patients with an active infection of the ear or at any other body site. Data Sources A CRF will be completed by the physician for all subjects at the consult visit, at the time of surgery, and 3 months post-operation. The subject will complete a Patient Evaluation Measure (PEM) at the 3 month post-operation visit to assess satisfaction with the outcome of the procedure and psychosocial well-being. Sample Size At least 30 patients who receive an EARFOLD® will be enrolled Data Analysis This study will provide a descriptive analysis only. AEs will be presented by site for each AE. AEs will also be presented cumulatively. The proportion of infections, re-operations, erosions and other complications of interest will be calculated. The data will be compared to a summary of AEs associated with conventional otoplasty obtained from a systematic review of the literature. Aesthetic outcome data will be presented based upon the completed PEM forms.

---

## Study status

Finalised

## Research institutions and networks

# Institutions

## Royal Free Hospital

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

### Study institution contact

Verga Anita CT.Disclosures@abbvie.com

Study contact

[CT.Disclosures@abbvie.com](mailto:CT.Disclosures@abbvie.com)

### Primary lead investigator

Verga Anita

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 15/06/2016

Actual: 15/06/2016

---

### Study start date

Planned: 31/12/2015

Actual: 28/06/2016

---

### **Date of final study report**

Planned: 18/03/2017

Actual: 22/03/2017

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Allergan

## Study protocol

[20160516 EarFold PMCF Protocol Final v2.pdf](#)(123.88 KB)

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

EU RMP category 3 (required)

## Methodological aspects

### Study type

### Study type list

**Study topic:**

Medical device

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

**Data collection methods:**

Primary data collection

---

**Main study objective:**

Characterise and assess the incidence rates of • Infections • Re-operations • Erosions in patients who receive at least one EARFOLD® implant.

## Study Design

**Non-interventional study design**

Cohort

## Population studied

**Short description of the study population**

Patients who receive at least one EARFOLD® implant.

---

**Age groups**

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

### **Estimated number of subjects**

30

## Study design details

### **Outcomes**

Infection Rates Re-operation Rates Erosion Rates, Other AEs

---

### **Data analysis plan**

Descriptive data analysis only. The proportion of infections, re-operations, erosions and other complications of interest will be calculated. The data will be compared to a summary of AEs associated with conventional otoplasty obtained from a systematic review of the literature.

## Documents

### **Study results**

[Post-Market Surveillance report - Final 28Feb2017 UBC.pdf](#)(111.11 KB)

---

## Data management

## Data sources

## Data sources (types)

Other

---

### Data sources (types), other

Prospective patient-based data collection

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### Check conformance

Unknown

---

### Check completeness

Unknown

---

### Check stability

Unknown

---

### Check logical consistency

Unknown

## Data characterisation

### Data characterisation conducted

Unknown